Sexual Health Protocol

Overview

Sexual health is not a single system. It is the intersection of endocrine signaling, vascular function, central nervous system pathways, psychological state, and relational context. A meaningful protocol approach has to acknowledge all five — addressing only one rarely produces durable change, and reaching for a peptide before evaluating the upstream contributors is one of the most common mistakes in this space.

This article is intentionally broader than the Libido Enhancement Protocol, which focuses narrowly on melanocortin agonists for desire. Here the goal is to step back and look at sexual function as a whole — what to evaluate before any pharmacology, which peptides have been investigated for which components of the system, where conventional medicine still leads (PDE5 inhibitors and hormone correction), and how to think about cycling and discontinuation.

The framing throughout is research-oriented. Most of the peptides discussed are not FDA-approved for sexual indications. PT-141 (bremelanotide) is the major exception, having received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women under the trade name Vyleesi. Everything else discussed below — kisspeptin-10, oxytocin analogs, gonadorelin used outside of fertility indications, BPC-157 — is investigated in research contexts.

Foundational Evaluation

Before considering any peptide, baseline data is essential. Sexual function complaints frequently resolve once an underlying contributor is identified. Skipping this step turns peptides into a guessing exercise.

Recommended Bloodwork

For most adults presenting with sexual health concerns, the following panel covers the high-yield contributors:

• Total testosterone — morning draw (8–10 AM), fasted preferred. Reference ranges vary by lab, but the commonly cited range for adult males is roughly 300–1000 ng/dL. Symptoms often track with the lower third of that range even when "normal."
• Free testosterone — calculated or measured directly. Often more clinically informative than total when SHBG is abnormal.
• SHBG (sex hormone-binding globulin) — high SHBG can produce symptoms of low free testosterone despite normal total values.
• Estradiol (sensitive assay) — both excess and deficiency contribute to libido and erectile complaints.
• Prolactin — markedly elevated prolactin (e.g., from a pituitary adenoma) is a classic and treatable cause of low libido and erectile dysfunction.
• TSH and free T4 — thyroid dysfunction in either direction affects libido and energy.
• Fasting glucose and HbA1c — metabolic dysfunction is a leading cause of vasculogenic erectile dysfunction.
• Lipid panel — atherosclerosis is the same disease whether it shows up in coronary arteries or penile arteries.
• Ferritin and CBC — iron status affects energy, mood, and sleep, all upstream of sexual function.
• 25-hydroxy vitamin D — low vitamin D correlates with low testosterone in observational data.
• DHEA-S — adrenal androgen reserve, sometimes relevant in older adults or those with adrenal concerns.

For women, the panel should also consider total and free testosterone (yes, women have it and it matters for desire), DHEA-S, estradiol with cycle context, and progesterone where indicated. See Female Considerations for additional notes.

Medications That Suppress Sexual Function

A surprisingly large fraction of sexual complaints are pharmacologic in origin. Before adding any new compound, audit what the patient or research subject is already taking:

• SSRIs and SNRIs — paroxetine, sertraline, fluoxetine, venlafaxine and others are well-documented contributors to decreased desire, delayed orgasm, anorgasmia, and erectile difficulty. A subset of users develop persistent symptoms after discontinuation (PSSD), an area of active research.
• Finasteride and dutasteride — 5-alpha reductase inhibitors used for hair loss and BPH. A minority of users report persistent sexual side effects after discontinuation (post-finasteride syndrome).
• Beta-blockers — particularly the older non-selective agents (propranolol). Newer selective agents and nebivolol are generally less problematic.
• Thiazide diuretics and certain other antihypertensives — frequently implicated in erectile complaints.
• Opioids — chronic opioid use suppresses the HPG axis, often producing measurable hypogonadism.
• Anti-androgens — spironolactone, ketoconazole, GnRH analogs used in oncology.
• Antipsychotics — particularly those that elevate prolactin (risperidone, paliperidone).

If a medication on this list is contributing, addressing it with the prescriber is upstream of any peptide intervention.

Lifestyle and Relational Factors

Sleep deprivation, untreated obstructive sleep apnea, chronic stress, alcohol use, and relationship distress are each independently sufficient to suppress sexual function. Sleep apnea in particular is associated with low testosterone and erectile dysfunction and is frequently undiagnosed. None of these respond to peptides, and chasing pharmacology while leaving them unaddressed is a recurring pattern.

Compounds Investigated for Sexual Health

The table below summarizes the primary compounds with research investigating sexual function endpoints. Dose ranges reflect what appears in published research literature; they are not clinical recommendations.

Compound	Mechanism	Research Dose Range	Route	Primary Research Target
PT-141 (bremelanotide)	MC3R/MC4R agonist	0.75–1.75 mg pre-event	Subcutaneous	Central desire and arousal
Kisspeptin-10	KISS1R agonist, upstream GnRH driver	~1 mcg/kg, varies by trial	Subcutaneous or IV in trials	HPG axis activation, sexual desire
Oxytocin	OXTR agonist	16–40 IU intranasal; lower SubQ in research	Intranasal preferred; SubQ in research	Pair-bonding, partner satisfaction
Gonadorelin	GnRH analog	100–200 mcg 2–3x weekly	Subcutaneous	HPG axis maintenance
hCG (prescription)	LH analog	250–500 IU 2–3x weekly	Subcutaneous	Testicular signaling, T preservation
DHEA	Adrenal androgen precursor	25–50 mg oral	Oral	Androgen reserve
Tadalafil (PDE5 inhibitor)	PDE5 inhibition, vascular	2.5–5 mg daily or 10–20 mg PRN	Oral	Erectile hemodynamics
Sildenafil (PDE5 inhibitor)	PDE5 inhibition, vascular	25–100 mg PRN	Oral	Erectile hemodynamics
BPC-157	Angiogenic, NO-modulating	200–500 mcg/day	Subcutaneous or oral	Speculative vascular support

A few notes on the table. hCG is a prescription medication in most jurisdictions and is included here because it appears frequently in HPG axis discussions. Tadalafil and sildenafil are not peptides; they are listed because honest treatment of male sexual health requires acknowledging that PDE5 inhibitors are the validated first-line therapy for erectile dysfunction. BPC-157 is included with explicit caveats — its role in sexual health is speculative and based on indirect angiogenic data.

Hormonal Axis Support

The hypothalamic-pituitary-gonadal (HPG) axis is the upstream regulator of sex hormone production. The hypothalamus releases GnRH in pulses, which drives pituitary LH and FSH, which drive gonadal testosterone (and in women, estrogen and progesterone) production. Suppression at any level produces downstream symptoms.

When sexual function complaints stem from a suboptimally functioning HPG axis — rather than from primary gonadal failure or central nervous system pathways — peptides that act upstream may be of interest in research contexts.

Kisspeptin-10 acts on KISS1R receptors in the hypothalamus and is the most upstream signal currently accessible pharmacologically. It triggers GnRH release rather than bypassing it, which preserves the pulsatile architecture of the axis. Recent human trials, including work from Imperial College London, have investigated kisspeptin in men with hypoactive sexual desire and reported activation of brain regions associated with sexual processing. The clinical picture is still developing.

Gonadorelin, a synthetic GnRH analog, is sometimes used in research and clinical contexts to maintain pituitary-testicular signaling, particularly when exogenous testosterone is being administered. Pulsatile administration matters — continuous GnRH stimulation paradoxically suppresses the axis (the basis of GnRH agonist use in oncology).

hCG mimics LH directly at the testicular level, bypassing the pituitary. It can preserve testicular size and intratesticular testosterone in men on TRT, but does not preserve hypothalamic or pituitary function. It is a prescription drug.

The general principle when working with the HPG axis is to avoid crashing it. Long-term high-dose exogenous testosterone without ancillary support produces secondary hypogonadism that may persist after discontinuation. See the Hormone Optimization Protocol and PCT Protocol for more detail.

Central and Arousal Pathways

Desire and arousal are produced in the brain, not in the genitals. This is why PDE5 inhibitors — which work peripherally on penile vasculature — fail to address libido complaints despite restoring erectile capacity.

PT-141 (bremelanotide) is the most studied tool for this central component. As an MC3R/MC4R agonist, it acts on hypothalamic and limbic circuits involved in sexual motivation. Its FDA approval for HSDD in premenopausal women in 2019 reflects placebo-controlled evidence of effect on desire endpoints. In male research populations, similar effects on desire and arousal are reported. The libido-specific dosing strategy, titration, and side effect profile (most commonly nausea, transient blood pressure increase, focal hyperpigmentation) are covered in detail in the Libido Enhancement Protocol.

Oxytocin is implicated in pair-bonding, partner-directed satisfaction, and the post-orgasmic refractory period. Research is preliminary and the effect sizes in human trials are modest and variable. Intranasal administration is the most studied route; subcutaneous administration is used in some research contexts but the central penetration question is unresolved. Oxytocin should not be expected to produce the kind of acute pre-event effect that PT-141 produces; the framing is more relational than pharmacological.

Vascular Component

Erectile function depends on the ability to deliver and trap blood in penile tissue. Endothelial dysfunction — driven by metabolic syndrome, diabetes, hypertension, dyslipidemia, smoking, and aging — is the single largest contributor to erectile dysfunction in adults.

PDE5 inhibitors are the first-line, well-validated therapy for this. They prolong the action of cyclic GMP downstream of nitric oxide signaling, allowing for adequate erectile response when desire and neural input are intact. Tadalafil at 2.5–5 mg daily produces continuous PDE5 inhibition without an event-tied administration, which many users prefer; it also has data for benign prostatic hyperplasia symptoms. Sildenafil at 25–100 mg as needed is the traditional event-tied option.

These are prescription drugs in most jurisdictions, are well characterized, and are typically more effective for the erectile component than any peptide. Acknowledging this honestly is part of an evidence-aligned protocol; peptides are not a substitute for PDE5 inhibitors when the issue is primarily vascular.

BPC-157 has been investigated for angiogenic and nitric-oxide-modulating effects in preclinical models. There is no human trial evidence supporting its use specifically for erectile function, and any role here is speculative. It is reasonable to mention in the broader context of vascular health (see Cardiovascular Protocol), but it should not be positioned as a primary tool for sexual health.

Protocol Structure

A reasonable phased approach for an adult presenting with sexual function concerns:

Phase 1 — Baseline and Lifestyle (Weeks 0–4)

• Complete the bloodwork panel above
• Document medications and identify candidates for adjustment with the prescribing clinician
• Address sleep duration and quality; screen for sleep apnea if snoring, witnessed apneas, daytime sleepiness, or weight changes are present
• Reduce or eliminate alcohol; address recreational substance use
• Establish baseline aerobic and resistance training; metabolic improvement supports endothelial function

Phase 2 — Reversible Factors (Weeks 4–8)

• Address identified deficiencies (vitamin D, ferritin, thyroid)
• Discuss medication substitutions if SSRIs or other suppressive agents are contributing
• Reassess subjective sexual function after 4–6 weeks of corrected reversibles before introducing pharmacology
• Consider a trial of low-dose daily tadalafil (2.5–5 mg) under physician supervision if erectile component is prominent and contraindications are absent

Phase 3 — Targeted Pharmacology (Weeks 8+)

If desire remains the primary issue after Phase 1 and Phase 2:

• Consider PT-141 as a pre-event tool per the Libido Enhancement Protocol
• Consider kisspeptin-based approaches in research contexts where HPG axis activation is the goal
• Address frank hypogonadism with appropriate hormonal correction rather than peptide-based workarounds

Phase 4 — Reassessment (Every 12 weeks)

• Repeat relevant labs at 12 weeks if hormonal interventions are ongoing
• Reassess subjective domains: desire, arousal, erectile function, orgasm, relational satisfaction
• De-escalate where possible; most of these tools are not lifelong commitments

Cycling and Discontinuation Considerations

The cycling logic varies by compound:

• PT-141 is on-demand. There is no daily dosing rationale, no cycle to run, and no discontinuation effect of clinical importance. Use it when needed; do not use it daily.
• Kisspeptin-10 in research protocols is typically administered intermittently rather than continuously. Continuous high-dose stimulation of the HPG axis can produce desensitization at multiple levels.
• Gonadorelin / hCG are typically pulsatile and time-limited unless used as ongoing TRT adjuncts. Long-term use without cycling carries the same axis-suppression considerations as direct testosterone.
• PDE5 inhibitors can be used as needed or daily; daily low-dose tadalafil does not require cycling.
• Oxytocin is generally used episodically in research; sustained high-dose intranasal administration is not well characterized.

For deeper treatment of cycling principles applicable across peptides, see Peptide Cycling and Tapering and Discontinuation.

Common Mistakes

• Stacking everything at once. Adding PT-141, kisspeptin, oxytocin, hCG, and tadalafil simultaneously eliminates any ability to attribute response or side effects. Sequence interventions.
• Skipping labs. Treating the symptom without the bloodwork wastes months and miscategorizes the problem. A man with a 200 ng/dL morning testosterone is not a PT-141 candidate first.
• Using hCG alone for low T without recovering the HPG axis. hCG bypasses the pituitary; long-term monotherapy can suppress endogenous LH production further. This is a setup for axis dependence.
• Reaching for Melanotan II for libido. It works, but the side effect profile (pigmentary changes, dysplastic nevi over time, broader melanocortin activity) makes PT-141 the more refined tool for desire specifically.
• Expecting peptides to fix relationship problems. Peptides modulate physiology. They do not address communication, attraction, conflict, or partner availability. A pharmacologic response without a relational change frequently produces frustration on both sides.
• Ignoring cardiovascular risk. PT-141 transiently raises blood pressure. Combining PDE5 inhibitors with nitrates is contraindicated. Cardiac evaluation precedes pharmacology in older adults or those with risk factors.
• Treating sleep apnea with peptides. It does not work. CPAP and weight management work.

When to Refer Out

Peptide research is not a substitute for medical evaluation. The following presentations warrant clinical workup before any peptide is considered:

• New-onset erectile dysfunction with cardiovascular risk factors — ED is an early marker of endothelial disease and may precede coronary events by several years.
• Sudden loss of libido with other systemic symptoms — fatigue, weight changes, headaches, or visual changes raise concern for pituitary disease.
• Markedly elevated prolactin — requires imaging to evaluate for prolactinoma.
• Hypogonadism with unclear cause — primary versus secondary hypogonadism requires differentiation; the workup is not a peptide question.
• Severe depression or anhedonia — sexual symptoms in this context are usually downstream of mood, and treatment of the mood disorder is primary.
• Neurological signs — numbness, weakness, autonomic symptoms suggesting neurogenic etiology.
• Persistent post-SSRI or post-finasteride sexual dysfunction — these are recognized syndromes that benefit from specialist familiarity.

Related Protocols

• Libido Enhancement Protocol — focused PT-141 and melanocortin-agonist protocol
• Andropause Support Protocol — age-related testosterone decline
• Hormone Optimization Protocol — broader HPG axis and hormonal balance
• Erectile Dysfunction Protocol — vascular-focused approach (forthcoming)
• Cardiovascular Protocol — endothelial and metabolic foundations
• Sleep Optimization Protocol — sleep as an upstream sexual health input
• PCT Protocol — restoring HPG axis after suppression
• Female Considerations — sex-specific notes on hormonal evaluation

Important Context and Disclaimer

This article is provided for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Most of the peptide compounds discussed — including kisspeptin-10, oxytocin (outside its specific approved obstetric indications), and gonadorelin used outside fertility settings — are not FDA-approved for sexual health applications. PT-141 (bremelanotide) is FDA-approved in the US under the trade name Vyleesi for hypoactive sexual desire disorder in premenopausal women; off-label use is common in the research literature but is not endorsed here. PDE5 inhibitors (sildenafil, tadalafil) and hCG are prescription drugs and should be used only under qualified medical supervision. Cardiovascular evaluation is appropriate prior to any pharmacologic intervention in older adults or those with risk factors. Consult a qualified clinician before beginning any protocol. Pepperpedia does not endorse the acquisition or use of unapproved substances.